In July 2022, Ablaze Pharma and Wenjiang District Government of Chengdu jointly signed the strategic agreement during the Conference of Major Advanced Manufacturing Projects by Foreign Direct Investment. About 26,000㎡ of industrial land is selected in the Chengdu Medical City, with an initial investment of 100 million USD to build-up an innovative R&D and manufacturing center for targeted radiation therapies, where five anti-tumor varieties are under research at present, varying from Ac-225 to Lu-177. Ablaze Pharma intends to introduce the world-class innovative targeted radiopharmaceutical therapies (TRT) product designs and clinical experiences into Wenjiang District and jointly building-up the industrial chains of innovative radioactive targeted drug together with the industrial advantages of Wenjiang District.
To
read more please visit:
Source: newswire